Tenofovir (all routes except local) - Medication and Pregnancy KB

Tenofovir (all routes except local)

Maternal consequences (as a whole)

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S5293 R13654	Zeng (Controls exposed to telbivudine), 2019	Adverse pregnancy	2nd and/or 3rd trimester	prospective cohort	exposed to other treatment, sick excluded	Adjustment: No Control group: telbivudine Exposed group: TDF (only) Indication: CHB	1.04 [0.30;3.54] ^C excluded (control group)	5/71 6/88	11	71		ref
S5712 R14210	Zeng (Controls unexposed, sick), 2019	Adverse pregnancy	2nd and/or 3rd trimester	prospective cohort	unexposed, sick	Adjustment: No Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB	1.09 [0.25;4.78] ^C	5/71 3/46	8	71		ref
S5304 R13748	Jourdain a, 2018	Maternal adverse event of grade 3 or 4 or serious adverse event	3rd trimester	randomized controlled trial	unexposed, sick	Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB	0.87 [0.53;1.43] ^C	41/168 44/163	85	168		ref
					Total	2 studies	0.89 [0.56;1.43]		93	239
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: Controls unexposed, sick;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 5293